

Feng-ming Tien

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9342272/publications.pdf>

Version: 2024-02-01

19
papers

334
citations

933447

10
h-index

839539

18
g-index

20
all docs

20
docs citations

20
times ranked

625
citing authors

#	ARTICLE	IF	CITATIONS
1	Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax. <i>Annals of Hematology</i> , 2020, 99, 501-511.	1.8	52
2	Clinical and microbiological characteristics of bloodstream infections among patients with haematological malignancies with and without neutropenia at a medical centre in northern Taiwan, 2008–2013. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 272-281.	2.5	41
3	GATA2 zinc finger 1 mutations are associated with distinct clinico-biological features and outcomes different from GATA2 zinc finger 2 mutations in adult acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2018, 8, 87.	6.2	34
4	Hyperleukocytosis is associated with distinct genetic alterations and is an independent poor-risk factor in <i>de novo</i> acute myeloid leukemia patients. <i>European Journal of Haematology</i> , 2018, 101, 86-94.	2.2	31
5	Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML. <i>Blood Advances</i> , 2021, 5, 2456-2466.	5.2	31
6	Concomitant <i>WT1</i> mutations predict poor prognosis in acute myeloid leukemia patients with double mutant <i>CEBPA</i> . <i>Haematologica</i> , 2018, 103, e510-e513.	3.5	29
7	Clinical characteristics and treatment outcomes of pulmonary invasive fungal infection among adult patients with hematological malignancy in a medical centre in Taiwan, 2008–2013. <i>Journal of Microbiology, Immunology and Infection</i> , 2020, 53, 106-114.	3.1	24
8	Hepatitis B reactivation among 1962 patients with hematological malignancy in Taiwan. <i>BMC Gastroenterology</i> , 2018, 18, 6.	2.0	20
9	Chronic disseminated candidiasis manifesting as hepatosplenic abscesses among patients with hematological malignancies. <i>BMC Infectious Diseases</i> , 2019, 19, 635.	2.9	19
10	Hepatitis B reactivation during treatment of tyrosine kinase inhibitors—Experience in 142 adult patients with chronic myeloid leukemia. <i>Leukemia Research</i> , 2019, 81, 95-97.	0.8	12
11	Polatuzumab vedotin–based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience. <i>Annals of Hematology</i> , 2022, 101, 349-358.	1.8	12
12	Distinct clinico-biological features in AML patients with low allelic ratio FLT3-ITD: role of allogeneic stem cell transplantation in first remission. <i>Bone Marrow Transplantation</i> , 2022, 57, 95-105.	2.4	8
13	Brentuximab vedotin as a salvage treatment for relapsed and refractory Hodgkin lymphoma patients in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 1466-1470.	1.7	6
14	Safety, Feasibility, and Effects of Short-Term Calorie Reduction during Induction Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma: A Pilot Study. <i>Nutrients</i> , 2021, 13, 3268.	4.1	6
15	ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden but not in those with high allele burden. <i>Blood Cancer Journal</i> , 2020, 10, 99.	6.2	5
16	Busulfan–containing conditioning regimens in allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: A Taiwan observational study. <i>Cancer Reports</i> , 2021, , e1488.	1.4	2
17	Feasibility, Process, and Effects of Short-Term Calorie Reduction in Cancer Patients Receiving Chemotherapy: An Integrative Review. <i>Nutrients</i> , 2020, 12, 2823.	4.1	1
18	Re-Examination of 2017 ELN Risk Classification By a Cohort of 739 De Novo aml Patients in Taiwan: Co-Occurring Poor-Risk Mutations May Further Predict Outcome in FLT3-ITD Patients. <i>Blood</i> , 2018, 132, 3977-3977.	1.4	1

#	ARTICLE	IF	CITATIONS
19	The Clinical Association and Prognostic Impact of IL1RAP Expression in Patients with De Novo Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 2705-2705.	1.4	0